

- Olanzapine 10 mg** Zyprexa 10mg Velotabs sugar-free | 28 tablet **[PoM]** £87.40 DT = £87.40
- Olanzapine 15 mg** Zyprexa 15mg Velotabs sugar-free | 28 tablet **[PoM]** £131.10 DT = £131.10
- Olanzapine 20 mg** Zyprexa 20mg Velotabs sugar-free | 28 tablet **[PoM]** £174.79 DT = £174.79

Orodispersible tablet

CAUTIONARY AND ADVISORY LABELS 2

EXCIPIENTS: May contain Aspartame

▶ **Olanzapine (Non-proprietary)**

- Olanzapine 5mg** Olanzapine 5mg orodispersible tablets sugar free sugar-free | 28 tablet **[PoM]** £6.86-£40.85 DT = £6.86
- Olanzapine 5mg** orodispersible tablets | 28 tablet **[PoM]** £30.00 DT = £29.35
- Olanzapine 10 mg** Olanzapine 10mg orodispersible tablets | 28 tablet **[PoM]** £50.00 DT = £49.00
- Olanzapine 10mg** orodispersible tablets sugar free sugar-free | 28 tablet **[PoM]** £11.50-£74.29 DT = £11.50
- Olanzapine 15 mg** Olanzapine 15mg orodispersible tablets sugar free sugar-free | 28 tablet **[PoM]** £11.65-£66.76 DT = £11.65
- Olanzapine 15mg** orodispersible tablets | 28 tablet **[PoM]** £48.82 DT = £48.82
- Olanzapine 20 mg** Olanzapine 20mg orodispersible tablets sugar free sugar-free | 28 tablet **[PoM]** £18.93-£96.14 DT = £18.93
- Olanzapine 20mg** orodispersible tablets | 28 tablet **[PoM]** £80.00 DT = £78.93
- ▶ **Zalasta** (Consilient Health Ltd)
- Olanzapine 5 mg** Zalasta 5mg orodispersible tablets sugar-free | 28 tablet **[PoM]** £40.85 DT = £6.86
- Olanzapine 10 mg** Zalasta 10mg orodispersible tablets sugar-free | 28 tablet **[PoM]** £74.20 DT = £11.50
- Olanzapine 15 mg** Zalasta 15mg orodispersible tablets sugar-free | 28 tablet **[PoM]** £111.43 DT = £11.65
- Olanzapine 20 mg** Zalasta 20mg orodispersible tablets sugar-free | 28 tablet **[PoM]** £148.57 DT = £18.93

F 401

Paliperidone

15-Jun-2017

- **DRUG ACTION** Paliperidone is a metabolite of risperidone.

● **INDICATIONS AND DOSE****Schizophrenia | Psychotic or manic symptoms of schizoaffective disorder**▶ **BY MOUTH**

- ▶ **Adult:** 6 mg once daily, dose to be taken in the morning, then adjusted in steps of 3 mg if required, dose to be adjusted over at least 5 days; usual dose 3–12 mg daily

TREVICTA® PRE-FILLED SYRINGES**Maintenance of schizophrenia in patients who are clinically stable on once-monthly intramuscular paliperidone**▶ **BY DEEP INTRAMUSCULAR INJECTION**

- ▶ **Adult:** Initially 175–525 mg every 3 months, adjusted according to response, to be administered into the deltoid or gluteal muscle, dose is based on previous once-monthly intramuscular paliperidone and should be initiated in place of the next scheduled dose—consult product literature

XEPLION® PRE-FILLED SYRINGES**Maintenance in schizophrenia in patients previously responsive to paliperidone or risperidone**▶ **BY DEEP INTRAMUSCULAR INJECTION**

- ▶ **Adult:** 150 mg for 1 dose on day 1, then 100 mg for 1 dose on day 8, to be injected into the deltoid muscle, dose subsequently adjusted at monthly intervals according to response; maintenance 75 mg once a month, alternatively maintenance 25–150 mg once a month, following the second dose, monthly maintenance doses can be administered into either the deltoid or gluteal muscle

● **CAUTIONS**

GENERAL CAUTIONS Cataract surgery (risk of intraoperative floppy iris syndrome) · dementia with Lewy bodies · elderly patients with dementia · elderly patients with risk factors for stroke · predisposition to gastrointestinal obstruction · prolactin-dependent tumours

SPECIFIC CAUTIONS

- ▶ With intramuscular use when transferring from oral to depot therapy, the dose by mouth should be reduced gradually

- **INTERACTIONS** → Appendix 1: paliperidone

● **SIDE-EFFECTS****GENERAL SIDE-EFFECTS**

- ▶ **Common or very common** Anxiety · appetite abnormal · asthenia · cardiac conduction disorders · cough · depression · diarrhoea · fever · gastrointestinal discomfort · headache · hyperglycaemia · hypertension · increased risk of infection · joint disorders · laryngeal pain · mood altered · nasal congestion · nausea · oral disorders · pain · skin reactions · vision disorders
- ▶ **Uncommon** Alopecia · anaemia · breast abnormalities · chest discomfort · chills · conjunctivitis · cystitis · dry eye · dysarthria · dysphagia · dyspnoea · ear pain · epistaxis · fall · gait abnormal · gastrointestinal disorders · generalised tonic-clonic seizure · hypoglycaemia · induration · malaise · menstrual cycle irregularities · muscle spasms · muscle weakness · oedema · palpitations · respiratory disorders · sensation abnormal · sexual dysfunction · sleep disorders · syncope · taste altered · thirst · thrombocytopenia · tinnitus · urinary disorders · vertigo
- ▶ **Rare or very rare** Angioedema · cerebrovascular insufficiency · coma · consciousness impaired · dandruff · diabetic ketoacidosis · dysphonia · eye disorders · flushing · glaucoma · hypothermia · ischaemia · jaundice · pancreatitis · polydipsia · posture abnormal · rhabdomyolysis · SIADH · sleep apnoea · vaginal discharge · water intoxication · withdrawal syndrome

SPECIFIC SIDE-EFFECTS

- ▶ **Common or very common**
- ▶ With oral use Weight decreased
- ▶ **Uncommon**
- ▶ With oral use Concentration impaired · confusion · diabetes mellitus
- ▶ **Frequency not known**
- ▶ With intramuscular use Injection site necrosis
- **PREGNANCY** Use only if potential benefit outweighs risk—toxicity in *animal* studies; if discontinuation during pregnancy is necessary, withdraw gradually.

TREVICTA® PRE-FILLED SYRINGES Manufacturer advises to consider long-acting nature of formulation—paliperidone detected in plasma up to 18 months after single dose.

- **BREAST FEEDING** Manufacturer advises avoid—present in milk.

TREVICTA® PRE-FILLED SYRINGES Manufacturer advises to consider long-acting nature of formulation—paliperidone detected in plasma up to 18 months after single dose.

- **HEPATIC IMPAIRMENT** Manufacturer advises caution in severe impairment (no information available).

● **RENAL IMPAIRMENT**

- ▶ With oral use Manufacturer advises avoid if creatinine clearance less than 10 mL/minute.
- ▶ With intramuscular use Manufacturer advises avoid if creatinine clearance less than 50 mL/minute.
- Dose adjustments** ▶ With oral use Manufacturer advises reduce initial dose to 3 mg once daily if creatinine clearance 50–80 mL/minute (max. 6 mg once daily). Manufacturer advises reduce initial dose to 1.5 mg once daily if creatinine clearance 10–50 mL/minute (max. 3 mg once daily).

TREVICTA® PRE-FILLED SYRINGES Dose adjustments Manufacturer advises dose should be adjusted and